Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level

Leukemia

Volumn 10, Issue 4, 1996, Pages 629-636

  Jamal, R ^a   Thomas, N S B ^a   Gale, R E ^a   Linch, D C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myeloid leukemia; p16

Indexed keywords

PROTEIN; RETINOBLASTOMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; DNA METHYLATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 0029911750     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mitchell C. Multi-stage carcinogenesis in paediatric and adult cancers. Eur J Cancer 1992; 28: 296-298.
2. Yarnold JR. What are cancer genes, and how do they upset cell behaviour? Eur J Cancer 1992; 28: 251-255.
3. Pitot HC. The molecular biology of carcinogenesis. Cancer 1993; 72 (Suppl.): 962-970.
4. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EYHP. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235: 1394-1399.
5. Goodrich DW, Lee WH. Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1993; 1155: 43-61.
6. Hollingsworth RE, Chen PL, Lee WH. Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr Opin Cell Biol 1993; 5: 194-200.
7. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424-429.
8. La Thangue NB. DP and E2F proteins: components of a heterodimeric transcription factor implicated in cell cycle control. Curr Opin Cell Biol 1994; 6: 443-450.
9. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993-1006.
10. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993; 73: 499-511.
11. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487-497.
12. Kato JY, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331-342.
13. 1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994; 14: 2077-2086.
14. Peters G. Stifled by inhibitions. Nature 1994; 371: 204-205.
15. Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994; 79: 181-184.
16. INK4B/MTS2-related cdk6 inhibitor, correlates with wild type pRb function. Genes Dev 1994; 8: 2939-2952.
17. Kamb A, Gruis NA, Weaver-Feldhause J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
18. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
19. Serrano M, Hannon GJ, Beach DA. New regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366: 704-707.
20. INKB is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
21. INK/MTS1 tumour suppressor gene product. EMBO J 1995; 14: 503-511.
22. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, Huebner K. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, cdk41 in melanoma. Cancer Res 1994; 54: 5269-5272.
23. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D, Kamb A, Liu Q, Harshman K, Tavtigian S, Cordon-Cardo C, Skolnick MH. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415-417.
24. Ink4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045-11049.
25. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA. p16 gene in uncultured tumors. Nature 1994; 370: 163-184.
26. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
27. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutations of the Mts1/cdk4 (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal cell carcinoma. Cancer Res 1994; 54: 3396-3397.
28. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H. Homozygous loss of the cyclin-dependent kinase-4 inhibitor (p16) gene in human leukaemias. Blood 1994; 84: 2431-2435.
29. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16) and MTS2 (p15) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukaemias. Blood 1994; 84: 4038-4044.
30. Quesnel B, Preudhomme C, Phillippe N, Vanrumbeke M, Dervite I, Lai IL, Bauters F, Wattel E, Fenaux P p16 gene homozygous deletions in acute lymphoblastic leukaemia. Blood 1995; 85: 657-663.
31. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
32. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Laboratory Press: Cold Spring Harbour, 1989; pp 1.2-7.87.
33. Hayashi K. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. PCR Meth APPL 1991; 1: 34-38.
34. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbour Laboratory Press: Cold Spring Harbour, 1988; pp 497-501.
35. Harris P, Ralph P. Human leukaemic models of myelomonocytic development: a review of the HL60 and U937 cell lines. J Leuk Biol 1995; 37: 407-410.
36. Macintyre EA, Roberts PJ, Abdul-Gaffar R, O'Flynn K, Pilkington GR, Farace F, Morgan J, Linch DC. Mechanism of human monocyte activation via the 40-kDa Fc receptor for IgG. J Immunol 1988; 141: 4333-4343.
37. Roberts PJ, Devalia V, Faint R, Pizzey A, Bainton AL, Thomas NSB, Pilkington GR, Linch DC. Differentiation linked activation of the respiratory burst in a monocytic cell line (U937) via FcγRII. J Immunol 1992; 147: 3104-3115.
38. Devalia V, Thomas NSB, Roberts PJ, Jones HM, Linch DC. Down-regulation of human protein kinase C is associated with terminal neutrophil differentiation. Blood 1992; 80: 68-76.
39. Roberts PJ, Jones M, Gale R, Thomas S, Tidman N, Linch DC. The c-myc oncogene is regulated independently of differentiation in myeloid cell lines. Leuk Res 1989; 13: 651-659.
40. 1 cells arrested with α-interferon. Oncogene 1992; 7: 783-788.
41. INK4 is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene 1994; 9: 3375-3378.
42. INK4. Cancer Res 1994; 54: 5816-5820.
43. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995; 55: 505-509.
44. Jamal R, Gale RE, Thomas NSB, Wheatley K, Linch DC. The retinoblastoma gene (RB1) in acute myeloid leukaemia: analysis of gene rearrangements, protein expression and comparison of disease outcome. Br J Haematol (submitted).
45. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS III, James DC. Cdk4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-5807.